Patent US4904472A successfully refreshed from Google Patents.
US4904472A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
Assignee: UVA Licensing and Ventures Group
•
Filing: 1987-04-10
•
Granted: 1990-02-27
•
Expires: 2007-04-10
Abstract
Abstract A method to enhance the efficacy of cardioversion, defibrillation, cardiac pacing, and cardiopulmonary resuscitation and to treat post-resuscitation asystole, bradyarrhythmias, electromechanical dissociation, and hemodynamic collapse by administering to a human or animal an effective amount of an adenosine antagonist that competitively inhibits adenosine or that reduces the level of adenosine present in myocardial and vascular tissues and associated fluids.
Inventors
- 👤 Luiz Belardinelli
- 👤 Robert C. Wesley, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 02:14
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
88 words
A method of enhancing the efficacy of cardiopulmonary resuscitation, comprising: applying an electrical defibrillatory shock to a human or animal in cardiac arrest to resuscitate the human or animal; administering to said human or animal an amount of adenosine antagonist sufficient to alleviate asystole and cardiac arrhythmia associated with said resuscitation, wherein said antagonist is selected from the group consisting of methylxanthines, imidazopyrimidine, pyrazolopyridine, etazolate, pyrazoloquinoline and triazoloquinazoline and wherein said antagonist competitively inhibits adenosine or reduces the level of adenosine present in myocardial tissue and associated fluids.
Claim 2
Independent Claim
88 words
A method of enhancing the efficacy of cardiopulmonary resuscitation, comprising: applying an electrical defibrillatory shock to a human or animal in cardiac arrest to resuscitate the human or animal; administering to said human or animal an amount of adenosine antagonist sufficient to alleviate asystole and cardiac arrhythmia associated with said resuscitation, wherein said antagonist is selected from the group consisting of methylxanthines, imidazopyrimidine, pyrazolopyridine, etazolate, pyrazoloquinoline and triazoloquinazoline and wherein said antagonist competitively inhibits adenosine or reduces the level of adenosine present in myocardial tissue and associated fluids.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein said antagonist is a methylxanthine.
Claim 4
Dependent Claim
21 words
The method of claim 2, wherein said methylxanthine is selected from the group consisting of 1,3,7-trimethylxanthine; 3,7-dimethylxanthine; 1,3-dimethylxanthine; aminophylline; and 8-(p-sulfophenyl)theophylline.
Claim 5
Dependent Claim
12 words
The method of claim 1, wherein said antagonist is a non-xanthine derivative.
Claim 6
Dependent Claim
22 words
The method of claim 4, wherein said non-xanthine derivative is selected from the group consisting of imidazopyrimidine, pyrazolopyridine, etazolate, pyrazoloquinoline and triazoloquinazoline.
Claim 7
Dependent Claim
17 words
The method of claim 1, wherein said antagonist is administered in a dose of about 0.1-20 mg/kg.
Claim 8
Dependent Claim
18 words
The method of claim 6, wherein said antagonist is administered in a dosage of from about 0.45-10 mg/kg.
Claim 9
Dependent Claim
17 words
The method of claim 6, wherein said antagonist is administered in a dosage of about 3-5 mg/kg.
Claim 10
Dependent Claim
26 words
The method of claim 1, wherein said administration is selected from the group consisting of intravenous injection, oral ingestion, local release and insertion of a suppository.
Claim 11
Dependent Claim
12 words
The method of claim 9, wherein said administration is by intravenous injection.
Claim 12
Dependent Claim
14 words
The method of claim 10, wherein said intravenous injection is a continuous intravenous injection.
Claim 13
Dependent Claim
18 words
The method of claim 11, wherein said continuous intravenous injection is at a rate of about 0.45 mg/kg/hr.
Claim 14
Dependent Claim
17 words
The method of claim 1, wherein said administering occurs concurrently with an α-adrenergic, β-adrenergic or dopaminergic agent.
Claim 15
Dependent Claim
25 words
The method of claim 13, wherein said adrenergic or dopaminergic agent is administered in a ratio of about 0.01:1.0 to 1.0:0.01 relative to said antagonist.
Claim 16
Dependent Claim
23 words
The method of claim 1, wherein said enhancing comprises enhancing the effectiveness of cardioversion, defibrillation, and cardiac pacing within the setting of resuscitation.
Claim 17
Independent Claim
78 words
A method for the treatment of post-resuscitation asystole, bradyarrhythmias, electro-mechanical dissociation, and hemodynamic collapse, comprising: applying an electrical difibrillatory shock to a human or animal in cardiac arrest to resuscitate the human or animal; administering to said human or animal an amount of adenosine antagonist sufficient to alleviate asystole, bradyarrhythmias, electromechanical dissociation and hemodynamic collapse associated with said resuscitation wherein said antagonist competitively inhibits adenosine or reduces the level of adenosine present in myocardial tissue and associated fluids.
Claim 18
Independent Claim
78 words
A method for the treatment of post-resuscitation asystole, bradyarrhythmias, electro-mechanical dissociation, and hemodynamic collapse, comprising: applying an electrical difibrillatory shock to a human or animal in cardiac arrest to resuscitate the human or animal; administering to said human or animal an amount of adenosine antagonist sufficient to alleviate asystole, bradyarrhythmias, electromechanical dissociation and hemodynamic collapse associated with said resuscitation wherein said antagonist competitively inhibits adenosine or reduces the level of adenosine present in myocardial tissue and associated fluids.
Claim 19
Dependent Claim
11 words
The method of claim 16, wherein said antagonist is a methylxanthine.
Claim 20
Dependent Claim
21 words
The method of claim 16, wherein said methylxanthine is selected from the group consisting of 1,3,7-trimethylxanthine; 3,7-dimethylxanthine; 1,3-dimethylxanthine; aminophylline; and 8-(p-sulfophenyl)theophylline.
Claim 21
Dependent Claim
12 words
The method of claim 16, wherein said antagonist is a non-xanthine derivative.
Claim 22
Dependent Claim
21 words
The method of claim 19, wherein said non-xanthine is selected from the group consisting of imidazopyrimidine, pyrazolopyridine, etazolate, pyrazoloquinoline and triazoloquinazoline.
Claim 23
Dependent Claim
17 words
The method of claim 16, wherein said antagonist is administered in a dose of about 0.1-20 mg/Kg.
Claim 24
Dependent Claim
18 words
The method of claim 21, wherein said antagonist is administered in a dose of from about 0.45-10 mg/Kg.
Claim 25
Dependent Claim
17 words
The method of claim 21, wherein said antagonist is administered in a dose of about 3-5 mg/Kg.
Claim 26
Dependent Claim
26 words
The method of claim 16, wherein said administration is selected from the group consisting of intravenous injection, oral ingestion, local release and insertion of a suppository.
Claim 27
Dependent Claim
12 words
The method of claim 24, wherein said administration is by intravenous injection.
Claim 28
Dependent Claim
14 words
The method of claim 25, wherein said intravenous injection is a continuous intravenous injection.
Claim 29
Dependent Claim
18 words
The method of claim 26, wherein said continuous intravenous injection is at a rate of about 0.45 mg/Kg/hr.
Claim 30
Dependent Claim
17 words
The method of claim 16, wherein said administering occurs concurrently with an α-adrenergic, β-adrenergic or dopaminergic agent.
Claim 31
Dependent Claim
26 words
The method of claim 28, wherein said adrenergic or dopaminergic agent is administered in a ratio of about 0.01:1.0 to about 1.0-0.01 relative to said antagonist.
References Cited (Backward Citations)
US4364922A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-26 | 1993-08-28 | 1994-02-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-26 | 1997-08-28 | 1998-02-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-26 | 2001-08-28 | 2002-02-27 | $7700.00 | Window Closed / Lapsed |